Helsinn Healthcare SA
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 1976-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.helsinn.com
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 64
- Registration Number
- NCT03151304
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Scripps Cancer Center-Mercy, San Diego, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 406
- Registration Number
- NCT03151408
- Locations
- 🇷🇴
clinical hospital Coltea Bld, Bucuresti, Romania
🇺🇸University Hospital Cleveland Medical Center, Cleveland, Ohio, United States
🇨🇳Hematology and Oncology, Changhwa Christian Hospital, Changhua, Taiwan
Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 3
- Registration Number
- NCT02883790
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori di Milano, Milan, Italy
🇮🇹I.E.O. Istituto Europeo di Oncologia, Milan, Italy
🇮🇹Policlinico S. Matteo di Pavia, Pavia, Italy
Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Helsinn Healthcare SA
- Registration Number
- NCT02877966
- Locations
- 🇦🇺
Gold Coast University Hospital, Southport, Australia
🇦🇺Bond University-Department of Nutrition & Dietetics, Robina, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Australia
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 441
- Registration Number
- NCT02557035
- Locations
- 🇧🇬
Specialized Hospital for Active Treatment in Oncology, Haskovo, Department of Medical Oncology, Haskovo, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment "Central Onco Hospital", Plovdiv, Department of Medical Oncology, Plovdiv, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment "Serdika", Sofia, Department of Medical Oncology, Sofia, Bulgaria
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 405
- Registration Number
- NCT02517021
- Locations
- 🇺🇦
Zakarpattia Regional Clinical Oncology Center, Department of Chemotherapy, Uzhhorod, Ukraine
🇺🇸Well Pharma Medical Research Corporation, Miami, Florida, United States
🇭🇷University Hospital Centre Zagreb "Jordanovac", Zagreb, Croatia
Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
- Conditions
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 498
- Registration Number
- NCT02383810
- Locations
- 🇵🇱
Wojewódzki Szpital Zespolony im. Rydygiera, Toruń, Poland
🇧🇾Healthcare Institution Minsk City Clinical Oncologic Dispensary, Minsk, Belarus
🇷🇺State Budgetary Institution of Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary", Arkhangelsk, Russian Federation
Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 32
- Registration Number
- NCT02118909
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 28
- Registration Number
- NCT02058784
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 45
- Registration Number
- NCT01993641
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States